Avadel Pharmaceuticals PLC (NASDAQ:AVDL) has been given a consensus rating of “Hold” by the seven research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $2.00.

Several analysts have commented on AVDL shares. Zacks Investment Research raised Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. ValuEngine upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Laidlaw set a $2.00 target price on Avadel Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, March 18th. Finally, LADENBURG THALM/SH SH cut Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Friday, February 8th.

Institutional investors and hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP raised its holdings in shares of Avadel Pharmaceuticals by 27.5% during the third quarter. Brandes Investment Partners LP now owns 6,335,548 shares of the company’s stock valued at $27,813,000 after buying an additional 1,365,442 shares during the last quarter. Morgan Stanley lifted its position in shares of Avadel Pharmaceuticals by 61.2% during the third quarter. Morgan Stanley now owns 777,272 shares of the company’s stock worth $3,412,000 after purchasing an additional 295,036 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Avadel Pharmaceuticals by 14.8% during the third quarter. Janney Montgomery Scott LLC now owns 227,573 shares of the company’s stock worth $999,000 after purchasing an additional 29,350 shares in the last quarter. Fosun International Ltd acquired a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth approximately $826,000. Finally, Broadfin Capital LLC lifted its position in shares of Avadel Pharmaceuticals by 11.1% during the fourth quarter. Broadfin Capital LLC now owns 3,102,673 shares of the company’s stock worth $8,005,000 after purchasing an additional 309,900 shares in the last quarter. 53.42% of the stock is currently owned by institutional investors and hedge funds.

AVDL traded down $0.09 on Tuesday, hitting $1.48. 192,187 shares of the company were exchanged, compared to its average volume of 145,391. Avadel Pharmaceuticals has a twelve month low of $1.47 and a twelve month high of $7.97. The stock has a market capitalization of $54.78 million, a price-to-earnings ratio of -0.74 and a beta of 1.81. The company has a debt-to-equity ratio of 41.63, a current ratio of 3.25 and a quick ratio of 3.02.

Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its quarterly earnings results on Friday, March 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.06. The company had revenue of $20.92 million during the quarter. Avadel Pharmaceuticals had a negative return on equity of 126.79% and a negative net margin of 92.29%.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Further Reading: Net Income

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.